ADMA Biologics to Report Third Quarter 2020 Financial Results and Business Highlights on November 5, 2020

Rhea-AI Summary

ADMA Biologics announced a live conference call on November 5, 2020, at 4:30 p.m. ET, to discuss its Q3 2020 financial results and business highlights. The call will be accessible via phone and an audio webcast, with an archived version available two hours post-event. ADMA specializes in manufacturing and marketing plasma-derived biologics, including ASCENIV™, BIVIGAM®, and NABI-HB®, approved by the FDA for treating immunodeficient patients. More information can be found on their website.

Positive

• ADMA operates FDA-approved manufacturing for plasma-derived biologics.
• The company has a dedicated conference call to discuss positive Q3 financial results.

Negative

• None.

Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Company will host a live conference call and audio webcast on Thursday, November 5, 2020 at 4:30 p.m. ET, to discuss its financial results and business highlights for the third quarter ended September 30, 2020.

To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 8185674. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM^® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB^® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA Bio Centers subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabiologics.com

INVESTOR RELATIONS CONTACT:
Sam Martin
Managing Director, Argot Partners | 212-600-1902 | sam@argotpartners.com

FAQ

What are the upcoming events for ADMA Biologics?

ADMA Biologics will host a conference call on November 5, 2020, to discuss its Q3 financial results.

When will ADMA Biologics announce its Q3 2020 financial results?

ADMA Biologics will announce its Q3 2020 financial results on November 5, 2020.

How can I listen to the ADMA Biologics conference call?

You can listen to the ADMA Biologics conference call by dialing (855) 884-8773 or through the audio webcast available on their website.